SUPPLEMENT
Q1 2026 — Other Financial Disclosures
Q1 2026PDF · 13 pages632 KB
Table 1: Sales by Segment 1 Table 2: Sales by Geographic Area 2 Table 3: Sales of Key Products/Franchises 3 - 7 Table 4: Condensed Consolidated Statement of Earnings - QTD 8 Table 5: Non-GAAP Adjusted Operational Sales Growth - QTD 9 Table 6: Non-GAAP Adjusted Net Earnings 10 Table 7: Non-GAAP P&L by Segment Reconciliation 2026 - QTD 11 Table 8: Non-GAAP P&L by Segment Reconciliation 2025 - QTD 12 First Quarter 2026 Other Financial Disclosures Table of Contents -- 1 of 13 -- Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) 2026 2025 Total Operations Currency Sales to customers by segment of business Innovative Medicine U.S. 8,871 $ 8,092 9.6 % 9.6 - International 6,555 5,781 13.4 4.3 9.1 15,426 13,873 11.2 7.4 3.8 MedTech U.S. 4,459 4,213 5.9 5.9 - International 4,177 3,807 9.7 3.2 6.5 8,636 8,020 7.7 4.6 3.1 U.S. 13,330 12,305 8.3 8.3 - International 10,732 9,588 11.9 3.9 8.0 Worldwide 24,062 $ 21,893 9.9 % 6.4 3.5 Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. FIRST QUARTER Percent Change -- 2 of 13 -- Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) 2026 2025 Total Operations Currency Sales to customers by geographic area U.S. 13,330 $ 12,305 8.3 % 8.3 - Europe 5,848 5,110 14.5 2.7 11.8 Western Hemisphere excluding U.S. 1,293 1,167 10.8 2.5 8.3 Asia-Pacific, Africa 3,591 3,311 8.5 6.1 2.4 International 10,732 9,588 11.9 3.9 8.0 Worldwide 24,062 $ 21,893 9.9 % 6.4 3.5 Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. FIRST QUARTER Percent Change -- 3 of 13 -- REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER INNOVATIVE MEDICINE SEGMENT (2) 2026 2025 Reported Operational (1) Currency ONCOLOGY US 3,615 $ 3,013 20.0% 20.0% - Intl 3,358 2,664 26.0% 15.3% 10.7% WW 6,973 5,678 22.8% 17.8% 5.0% DARZALEX US 2,208 1,829 20.7% 20.7% - Intl 1,756 1,409 24.7% 14.0% 10.7% WW 3,964 3,237 22.5% 17.8% 4.7% CARVYKTI US 433 318 36.2% 36.2% - Intl 164 51 * * * WW 597 369 62.1% 57.4% 4.7% TECVAYLI US 127 105 20.6% 20.6% - Intl 74 46 63.1% 52.1% 11.0% WW 202 151 33.5% 30.1% 3.4% TALVEY US 101 68 48.5% 48.5% - Intl 51 18 * * * WW 152 86 76.7% 72.8% 3.9% RYBREVANT / LAZCLUZE US 175 113 55.1% 55.1% - Intl 82 28 * * * WW 257 141 82.7% 80.5% 2.2% ERLEADA US 342 292 17.3% 17.3% - Intl 607 479 26.7% 15.5% 11.2% WW 949 771 23.1% 16.2% 6.9% IMBRUVICA US 143 235 (39.1)% (39.1)% - Intl 517 474 9.1% (1.4)% 10.5% WW 660 709 (6.9)% (13.9)% 7.0% OTHER ONCOLOGY (3) US 85 54 58.8% 58.8% - Intl 106 160 (33.9)% (36.3)% 2.4% WW 192 214 (10.6)% (12.5)% 1.9% See footnotes at end of schedule % Change -- 4 of 13 -- REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER 2026 2025 Reported Operational (1) Currency IMMUNOLOGY US 1,855 $ 2,196 (15.5)% (15.5)% - Intl 1,524 1,510 0.9% (6.4)% 7.3% WW 3,380 3,707 (8.8)% (11.8)% 3.0% TREMFYA US 1,042 599 73.9% 73.9% - Intl 566 356 58.9% 46.8% 12.1% WW 1,608 956 68.3% 63.8% 4.5% SIMPONI / SIMPONI ARIA US 269 292 (7.8)% (7.8)% - Intl 378 366 3.0% (4.1)% 7.1% WW 647 659 (1.7)% (5.7)% 4.0% REMICADE US 269 314 (14.4)% (14.4)% - US Exports (4) 18 10 78.6% 78.6% - Intl 136 143 (4.8)% (10.5)% 5.7% WW 422 467 (9.5)% (11.2)% 1.7% STELARA US 220 981 (77.6)% (77.6)% - Intl 435 644 (32.4)% (37.7)% 5.3% WW 656 1,625 (59.7)% (61.7)% 2.0% OTHER IMMUNOLOGY US 38 1 * * - Intl 9 0 * * * WW 46 1 * * * NEUROSCIENCE US 1,494 968 54.3% 54.3% - Intl 681 679 0.3% (6.3)% 6.6% WW 2,175 1,647 32.0% 29.3% 2.7% SPRAVATO US 406 276 47.0% 47.0% - Intl 61 43 42.4% 28.7% 13.7% WW 468 320 46.4% 44.5% 1.9% CAPLYTA (5) US 270 - * * - Intl - - - - - WW 270 - * * - INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA US 758 625 21.2% 21.2% - Intl 280 277 1.1% (4.9)% 6.0% WW 1,038 903 15.0% 13.2% 1.8% CONCERTA / Methylphenidate US 22 38 (43.4)% (43.4)% - Intl 115 110 4.3% (0.6)% 4.9% WW 136 148 (8.0)% (11.7)% 3.7% OTHER NEUROSCIENCE US 38 28 32.6% 32.6% - Intl 224 248 (9.7)% (16.3)% 6.6% WW 262 277 (5.4)% (11.3)% 5.9% See footnotes at end of schedule % Change -- 5 of 13 -- REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER 2026 2025 Reported Operational (1) Currency PULMONARY HYPERTENSION (PH) US 831 $ 744 11.7% 11.7% - Intl 304 281 8.2% 1.0% 7.2% WW 1,135 1,025 10.7% 8.7% 2.0% UPTRAVI US 385 365 5.4% 5.4% - Intl 98 86 14.3% 5.1% 9.2% WW 483 451 7.1% 5.4% 1.7% OPSUMIT / OPSYNVI US 433 363 19.3% 19.3% - Intl 172 159 8.7% 1.7% 7.0% WW 606 522 16.1% 14.0% 2.1% OTHER PULMONARY HYPERTENSION US 12 15 (21.1)% (21.1)% - Intl 34 37 (8.3)% (11.8)% 3.5% WW 46 52 (12.1)% (14.5)% 2.4% INFECTIOUS DISEASES (ID) US 342 315 8.6% 8.6% - Intl 547 487 12.2% 1.3% 10.9% WW 889 802 10.8% 4.1% 6.7% EDURANT / rilpivirine US 7 8 (13.1)% (13.1)% - Intl 402 350 14.8% 3.2% 11.6% WW 409 358 14.1% 2.8% 11.3% PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA US 334 305 9.5% 9.5% - Intl 109 98 11.2% 0.7% 10.5% WW 443 403 10.0% 7.4% 2.6% OTHER INFECTIOUS DISEASES US 1 2 (56.9)% (56.9)% - Intl 36 39 (8.3)% (14.7)% 6.4% WW 37 41 (10.4)% (16.5)% 6.1% CARDIOVASCULAR / METABOLISM / OTHER (CVM) US 734 855 (14.2)% (14.2)% - Intl 142 158 (10.4)% (17.5)% 7.1% WW 876 1,013 (13.6)% (14.7)% 1.1% XARELTO US 642 690 (7.0)% (7.0)% - Intl - - - - - WW 642 690 (7.0)% (7.0)% - OTHER US 91 165 (44.5)% (44.5)% - Intl 142 158 (10.4)% (17.5)% 7.1% WW 233 323 (27.8)% (31.2)% 3.4% TOTAL PH, ID, CVM US 1,907 1,914 (0.4)% (0.4)% - Intl 993 926 7.1% (2.0)% 9.1% WW 2,899 2,840 2.1% (0.9)% 3.0% TOTAL INNOVATIVE MEDICINE US 8,871 8,092 9.6% 9.6% - Intl 6,555 5,781 13.4% 4.3% 9.1% WW 15,426 $ 13,873 11.2% 7.4% 3.8% See footnotes at end of schedule % Change -- 6 of 13 -- REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER MEDTECH SEGMENT (2) 2026 2025 Reported Operational (1) Currency CARDIOVASCULAR US 1,399 1,261 10.9% 10.9% - Intl 978 842 16.1% 9.9% 6.2% WW 2,377 2,103 13.0% 10.5% 2.5% ELECTROPHYSIOLOGY US 736 684 7.6% 7.6% - Intl 753 638 18.0% 11.7% 6.3% WW 1,489 1,323 12.6% 9.5% 3.1% ABIOMED US 389 339 14.5% 14.5% - Intl 100 81 23.5% 13.9% 9.6% WW 488 420 16.3% 14.4% 1.9% SHOCKWAVE US 242 206 17.8% 17.8% - Intl 63 52 21.3% 19.3% 2.0% WW 305 258 18.5% 18.1% 0.4% OTHER CARDIOVASCULAR US 32 32 0.7% 0.7% - Intl 62 72 (13.4)% (17.5)% 4.1% WW 94 103 (9.1)% (11.9)% 2.8% SURGERY US 1,046 1,002 4.4% 4.4% - Intl 1,465 1,394 5.1% (1.1)% 6.2% WW 2,511 2,396 4.8% 1.2% 3.6% ADVANCED US 477 457 4.2% 4.2% - Intl 646 616 4.9% (1.0)% 5.9% WW 1,123 1,073 4.6% 1.2% 3.4% GENERAL US 569 544 4.5% 4.5% - Intl 819 778 5.2% (1.3)% 6.5% WW 1,388 1,323 4.9% 1.1% 3.8% See footnotes at end of schedule % Change -- 7 of 13 -- REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER 2026 2025 Reported Operational (1) Currency VISION US 579 566 2.4% 2.4% - Intl 785 713 10.1% 4.6% 5.5% WW 1,365 1,279 6.7% 3.6% 3.1% CONTACT LENSES / OTHER US 468 452 3.7% 3.7% - Intl 501 467 7.2% 1.7% 5.5% WW 969 919 5.5% 2.7% 2.8% SURGICAL US 111 114 (2.9)% (2.9)% - Intl 285 246 15.6% 10.1% 5.5% WW 396 361 9.7% 6.0% 3.7% ORTHOPAEDICS US 1,435 1,384 3.7% 3.7% - Intl 948 857 10.6% 2.4% 8.2% WW 2,383 2,241 6.3% 3.2% 3.1% HIPS US 277 263 5.2% 5.2% - Intl 159 146 8.9% 0.3% 8.6% WW 436 409 6.5% 3.5% 3.0% KNEES US 239 231 3.3% 3.3% - Intl 181 158 14.6% 6.5% 8.1% WW 420 389 7.9% 4.6% 3.3% TRAUMA US 532 502 6.1% 6.1% - Intl 301 270 11.4% 3.1% 8.3% WW 833 772 8.0% 5.0% 3.0% SPINE, SPORTS & OTHER US 387 388 (0.1)% (0.1)% - Intl 307 283 8.4% 0.7% 7.7% WW 694 671 3.5% 0.2% 3.3% TOTAL MEDTECH US 4,459 4,213 5.9% 5.9% - Intl 4,177 3,807 9.7% 3.2% 6.5% WW 8,636 $ 8,020 7.7% 4.6% 3.1% * Percentage greater than 100% or not meaningful (1) Operational growth excludes the effect of translational currency (2) Unaudited (3) Includes the sales of ZYTIGA which were previously disclosed separately (4) Reported as U.S. sales (5) Acquired with Intra-Cellular Therapies on April 2, 2025 Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely % Change -- 8 of 13 -- Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers 24,062 $ 100.0 21,893 $ 100.0 9.9 Cost of products sold 8,106 33.7 7,357 33.6 10.2 Gross Profit 15,956 66.3 14,536 66.4 9.8 Selling, marketing and administrative expenses 6,034 25.1 5,112 23.3 18.0 Research and development expense 3,527 14.7 3,225 14.7 9.4 In-process research and development impairments 36 0.1 - - Interest (income) expense, net 43 0.2 (128) (0.6) Other (income) expense, net 294 1.2 (7,321) (33.4) Restructuring 32 0.1 17 0.1 Earnings before provision for taxes on income 5,990 24.9 13,631 62.3 (56.1) Provision for taxes on income 755 3.1 2,632 12.1 (71.3) Net earnings 5,235 $ 21.8 10,999 $ 50.2 (52.4) Net earnings per share (Diluted) 2.14 $ 4.54 $ (52.9) Average shares outstanding (Diluted) 2,445.2 2,423.8 Effective tax rate 12.6 % 19.3 % Adjusted earnings before provision for taxes and net earnings (1) Earnings before provision for taxes on income 7,821 $ 32.5 8,011 $ 36.6 (2.4) Net earnings 6,614 $ 27.5 6,706 $ 30.6 (1.4) Net earnings per share (Diluted) 2.70 $ 2.77 $ (2.5) Effective tax rate 15.4 % 16.3 % (1) See Reconciliation of Non-GAAP Financial Measures. FIRST QUARTER 2026 2025 -- 9 of 13 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Innovative Medicine MedTech Total WW As Reported 11.2% 7.7% 9.9% U.S. 9.6% 5.9% 8.3% International 13.4% 9.7% 11.9% WW Currency 3.8 3.1 3.5 U.S. - - - International 9.1 6.5 8.0 WW Operational 7.4% 4.6% 6.4% U.S. 9.6% 5.9% 8.3% International 4.3% 3.2% 3.9% Caplyta (1.9) (1.2) U.S. (3.3) (2.2) International 0.0 0.0 All Other Acquisitions and Divestitures (A&D) 0.1 0.1 0.1 U.S. 0.0 0.2 0.1 International 0.2 0.0 0.1 WW Adjusted Operational Ex A&D 5.6% 4.7% 5.3% U.S. 6.3% 6.1% 6.2% International 4.5% 3.2% 4.0% Adjusted Operational Sales Growth FIRST QUARTER 2026 ACTUAL vs. 2025 ACTUAL Segments Note: Percentages are based on actual, non-rounded figures and may not sum -- 10 of 13 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures (Dollars in Millions Except Per Share Data) 2026 2025 Net Earnings, after tax- as reported $5,235 $10,999 Pre-tax Adjustments Intangible Asset Amortization expense 1,247 1,120 Litigation related 330 (6,966) Orthopaedics Separation related 119 - Acquisition, integration and divestiture related 96 132 Restructuring related 1 62 55 IPR&D impairments 36 - (Gains)/losses on securities (59) 39 Tax Adjustments Tax impact on special item adjustments 2 (424) 1,315 Tax legislation and other tax related (28) 12 Adjusted Net Earnings, after tax $6,614 $6,706 Average shares outstanding (Diluted) 2,445.2 2,423.8 Adjusted net earnings per share (Diluted) $2.70 $2.77 Operational adjusted net earnings per share (Diluted) $2.57 Notes: 1 2 First Quarter In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expense of $7 million in the fiscal first quarter of 2026 and $55 million in the fiscal first quarter of 2025 primarily includes costs related to market and product exits. This program was substantially completed in Q4 2025. In fiscal 2025, the company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. The restructuring expense of $55 million in the fiscal first quarter of 2026 primarily includes costs related to product exits. This program is expected to be substantially completed by the end of fiscal year 2026. The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings. -- 11 of 13 -- Year to Date Innovative Medicine First Quarter Mar. 29, 2026 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Orthopaedics Separation Related Tax legislation and other tax related First Quarter Mar. 29, 2026 Non-GAAP Cost of products sold 4,390 $ (763) (10) 3,617 $ Selling, marketing and admin expenses 2,918 2,918 Research and development expense 2,813 2,813 Other segment items (12) (40) (46) 55 (43) Adjusted Income Before Tax by Segment 5,317 763 40 - - 56 (55) - - 6,121 MedTech First Quarter Mar. 29, 2026 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Orthopaedics Separation Related Tax legislation and other tax related First Quarter Mar. 29, 2026 Non-GAAP Cost of products sold 3,701 $ (484) (25) 3,192 $ Selling, marketing and admin expenses 2,906 2,906 Research and development expense 714 714 Other segment items 76 41 (36) (37) (27) 4 (119) (98) Adjusted Income Before Tax by Segment 1,239 484 (41) 36 62 27 (4) 119 - 1,922 Expenses not allocated to segments First Quarter Mar. 29, 2026 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Orthopaedics Separation Related Tax legislation and other tax related First Quarter Mar. 29, 2026 Non-GAAP Cost of products sold 15 $ 15 $ Selling, marketing and admin expenses 210 210 Research and development expense - - Other segment items 341 (331) (13) (3) Adjusted Income Before Tax by Segment (566) - 331 - - 13 - - - (222) Johnson & Johnson Consolidated First Quarter Mar. 29, 2026 GAAP Intangible asset amortization Litigation related In-process research and development impairments Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Orthopaedics Separation Related Tax legislation and other tax related First Quarter Mar. 29, 2026 Non-GAAP Cost of products sold 8,106 $ (1,247) (25) (10) 6,824 $ Selling, marketing and admin expenses 6,034 6,034 Research and development expense 3,527 3,527 Other (Income) / Expense 294 (330) (5) (86) 59 (119) (187) In-process research and development impairments 36 (36) - Interest (Income)/Expense 43 43 Restructuring 32 (32) - Adjusted Income Before Tax 5,990 1,247 330 36 62 96 (59) 119 - 7,821 Provision for taxes on income 755 240 72 8 70 22 (13) 25 28 1,207 Net Earnings 5,235 $ 1,007 258 28 (8) 74 (46) 94 (28) 6,614 Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions -- 12 of 13 -- Innovative Medicine First Quarter March 30, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related First Quarter March 30, 2025 Non-GAAP Cost of products sold 4,020 $ (649) 3,371 Selling, marketing and admin expenses 2,261 2,261 Research and development expense 2,548 2,548 Other segment items (166) - - - (20) (18) - (204) Adjusted Income Before Tax by Segment 5,210 649 - - 20 18 - 5,897 MedTech First Quarter March 30, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related First Quarter March 30, 2025 Non-GAAP Cost of products sold 3,326 $ (471) (8) (52) 2,795 Selling, marketing and admin expenses 2,656 2,656 Research and development expense 677 (6) 671 Other segment items (60) - - (47) (54) (21) - (182) Adjusted Income Before Tax by Segment 1,421 471 - 55 112 21 - 2,080 Expenses not allocated to segments First Quarter March 30, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related First Quarter March 30, 2025 Non-GAAP Cost of products sold 11 $ 11 Selling, marketing and admin expenses 195 195 Research and development expense - Other segment items (7,206) - 6,966 - - - - (240) Adjusted Income Before Tax by Segment 7,000 - (6,966) - - - - 34 Johnson & Johnson Consolidated First Quarter March 30, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related First Quarter March 30, 2025 Non-GAAP Cost of products sold 7,357 $ (1,120) (8) (52) - 6,177 Selling, marketing and admin expenses 5,112 5,112 Research and development expense 3,225 (6) 3,219 Other (Income) / Expense (7,321) - 6,966 (30) (74) (39) (498) In-process research and development impairments - - Interest (Income)/Expense (128) (128) Restructuring 17 (17) - Adjusted Income Before Tax 13,631 1,120 (6,966) 55 132 39 - 8,011 Provision for taxes on income 2,632 188 (1,553) 11 30 9 (12) 1,305 Net Earnings 10,999 932 (5,413) 44 102 30 12 6,706 Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions Year to Date -- 13 of 13 --